Tempest Therapeutics (NASDAQ: TPST)
FY 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-12-20 | ||||||
REV |
FY 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-11-09 | ||||||
REV |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Tempest Therapeutics (NASDAQ: TPST) through any online brokerage.
Other companies in Tempest Therapeutics’s space includes: Biocept (NASDAQ:BIOC), Monopar Therapeutics (NASDAQ:MNPR), Humanigen (NASDAQ:HGEN), Indaptus Therapeutics (NASDAQ:INDP) and Sio Gene Therapies (NASDAQ:SIOX).
The latest price target for Tempest Therapeutics (NASDAQ: TPST) was reported by Cantor Fitzgerald on Friday, August 12, 2022. The analyst firm set a price target for 4.00 expecting TPST to rise to within 12 months (a possible 83.49% upside). 50 analyst firms have reported ratings in the last year.
The stock price for Tempest Therapeutics (NASDAQ: TPST) is $2.18 last updated August 12, 2022, 8:00 PM UTC.
The next Tempest Therapeutics (TPST) dividend date is projected to be Thursday, September 1, 2022.
Tempest Therapeutics’s FY earnings are confirmed for Wednesday, December 20, 2023.
There is no upcoming split for Tempest Therapeutics.
Tempest Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.